BRIEF-Rigel restructures to focus on Fostamatinib commercialization

* Rigel restructures to focus on fostamatinib commercialization
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.